Literature DB >> 29317375

Does doxorubicin survive thermal ablation? Results of an ex vivo bench top study.

Joseph D Morrison1, Collin K Schlager2, Amanda E Lee3, Richard B van Breemen3, Ron C Gaba2.   

Abstract

PURPOSE: We aimed to test the hypothesis that doxorubicin (DOX) survives thermal ablative heating in an ex vivo model of combined transarterial chemoembolization (TACE) and thermal ablation.
METHODS: Fresh porcine psoas major muscle (3 samples, 15×10×3 cm) was submerged in aqueous DOX solution (60 µg/mL, 0.1 M) for 24 hours to passively saturate tissue. DOX-infused tissue was then dried and treated with microwave ablation (MWA) using a 2.45 GHz antenna at 65 W for 2, 5, and 10 minutes. Ablations were repeated in triplicate (9 total). Tissue was then sampled at both ablated and unablated control sites, and DOX concentration was quantified via ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), with samples analyzed in triplicate. Tissue DOX levels in ablation and control groups were compared using one-way ANOVA.
RESULTS: Homogeneous DOX uptake into porcine tissue was evident in all three samples. Mean DOX concentration in unablated tissue was 8.0±2.2 µg/mL. MWA was technically successful in all 9 procedures (100%), with tissue heating to 95-100°C. Mean tissue DOX concentration showed progressive reduction with increasing ablation time, measuring 6.7±1.3, 4.9±0.9, and 4.8±1.3 µg/mL in MWA-treated tissue after 2, 5, and 10 minutes, respectively. Differences in tissue DOX levels between unablated tissue and MWA groups were statistically significant (P < 0.001).
CONCLUSION: Contrary to the initial hypothesis, tissue DOX concentration progressively decreased after MWA of longer ablation times. These results suggest that TACE followed by ablation may result in lower intratumoral DOX than would otherwise be anticipated for TACE alone.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29317375      PMCID: PMC5765925          DOI: 10.5152/dir.2018.17382

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  6 in total

Review 1.  Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Qi-Wen Chen; Hai-Feng Ying; Song Gao; Ye-Hua Shen; Zhi-Qiang Meng; Hao Chen; Zhen Chen; Wen-Jing Teng
Journal:  Clin Res Hepatol Gastroenterol       Date:  2015-10-01       Impact factor: 2.947

2.  Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants.

Authors:  Julien Namur; Steven J Citron; Marty T Sellers; Mark H Dupuis; Michel Wassef; Michel Manfait; Alexandre Laurent
Journal:  J Hepatol       Date:  2011-05-18       Impact factor: 25.083

3.  Potential for therapy of drugs and hyperthermia.

Authors:  G M Hahn
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

4.  Confirmation of drug delivery after liver chemoembolization: direct tissue doxorubicin measurement by UHPLC-MS-MS.

Authors:  Sigrid Baumgarten; Ron C Gaba; Richard B van Breemen
Journal:  Biomed Chromatogr       Date:  2012-03-27       Impact factor: 1.902

5.  2004 Dr. Gary J. Becker Young Investigator Award: Relative thermosensitivity of cytotoxic drugs used in transcatheter arterial chemoembolization.

Authors:  Kamran Ahrar; Robert A Newman; Jihai Pang; Mary K Vijjeswarapu; Michael J Wallace; Kenneth C Wright
Journal:  J Vasc Interv Radiol       Date:  2004-09       Impact factor: 3.464

6.  Four new degradation products of doxorubicin: An application of forced degradation study and hyphenated chromatographic techniques.

Authors:  Dheeraj Kaushik; Gulshan Bansal
Journal:  J Pharm Anal       Date:  2015-05-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.